SCHEMBL30611680

SCHEMBL30611680

O=C(NS(=O)(=O)c1cccc(N2CCC(O)C2)n1)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 2/20 0.43
▸ KIF18A Q8NI77 5/20 0.39
▸ P2RY12 Q9H244 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ ACACB O00763 1/20 0.37
▸ CTSS P25774 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ P2RX7 Q99572 1/20 0.37
▸ PRKDC P78527 1/20 0.36
▸ STS P08842 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.36
▸ HSD11B1 P28845 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ JAK1 P23458 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22116366 1.00 ABL1 (0.43) ABL1KIF18AP2RY12IRAK4ACACB
SCHEMBL30611688 1.00 ABL1 (0.43) ABL1KIF18AP2RY12IRAK4ACACB
SCHEMBL22116414 1.00 ABL1 (0.43) ABL1KIF18AP2RY12IRAK4ACACB
SCHEMBL22116413 0.92 HPGD (0.39) ABL1KIF18AP2RY12ACACBCTSS
SCHEMBL22116343 0.84 ACACB (0.46) KIF18AACACB
SCHEMBL22116346 0.82 KIF18A (0.50) KIF18A
SCHEMBL30611713 0.81 PTGER4 (0.42) KIF18APDE10AHSD11B1CYP3A4CYP2C19
SCHEMBL30611682 0.81 ATR (0.34) ACACBHPGDSTSCYP1A2CYP3A4
SCHEMBL22116332 0.80 HSD11B1 (0.44) KIF18AACACBHPGDSTSHSD11B1
SCHEMBL30611785 0.79 HSD11B1 (0.48) KIF18AACACBHPGDSTSHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897832-B1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE NOVARTIS AG (CH) 2023-10-11 — — EP claimed
EP-3897832-B1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE NOVARTIS AG (CH) 2023-10-11 — — EP disclosed
Send feedback